echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Clinical research reveals the contribution of tepotinib to patients with advanced liver cancer

    Br J Cancer: Clinical research reveals the contribution of tepotinib to patients with advanced liver cancer

    • Last Update: 2021-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Liver cancer is the third leading cause of cancer-related deaths worldwide, with more than 780,000 people dying from the disease every year.


    Liver cancer is the third leading cause of cancer-related deaths worldwide, with more than 780,000 people dying from the disease every year.


    Previous studies have shown that HCC testing is still late, and only about 30-40% of American/European patients can be treated at the time of diagnosis.




    This phase 1b/2 clinical study aims to evaluate the effect of tepotinib in patients with advanced hepatocellular carcinoma (aHCC) overexpressing MET treated with sorafenib in the United States/Europe.


    This phase 1b/2 clinical study aims to evaluate the effect of tepotinib in patients with advanced hepatocellular carcinoma (aHCC) overexpressing MET treated with sorafenib in the United States/Europe.



    Percentage of patients with 12-week progression-free survival

    Percentage of patients with 12-week progression-free survival

    In Phase 1b of the trial, patients received 300 or 500 mg of Tepotinib daily.


    The primary endpoints of the trial are dose-limiting toxicity (DLT; stage 1b) and 12-week progression-free survival (PFS; stage 2).



    Kaplan-Meier curves of PFS, TTP and OS of patients in the phase 2 study

    Kaplan-Meier curves of PFS, TTP and OS of patients in the phase 2 study

    All in all, the clinical trial results revealed that Tepotinib is well tolerated and has shown promising efficacy in RP2D (500mg) .


    Tepotinib is well tolerated and has shown promising effects in RP2D (500mg).



    org/10.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.